Galunisertib - Eli Lilly

Drug Profile

Galunisertib - Eli Lilly

Alternative Names: LY-2157299

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Eli Lilly; National Cancer Institute (USA); University of Oklahoma; Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Breast cancer; Glioblastoma; Liver cancer; Pancreatic cancer; Rectal cancer
  • Phase I/II Colorectal cancer; Glioma; Non-small cell lung cancer
  • Phase I Sarcoma; Solid tumours
  • No development reported Cancer

Most Recent Events

  • 28 Aug 2018 Eli Lilly completes a phase I/II trial in Non-small cell lung cancer, Glioblastoma and Liver cancer (Combination therapy, Second-line therapy or greater) in Germany, Spain and USA (PO) (NCT02423343)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top